Comprehensive Analysis of U.S. Patent 8,133,883: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 8,133,883, granted on March 13, 2012, to AstraZeneca AB, pertains to specific pharmaceutical compositions and methods involving kinase inhibitors, particularly targeting diseases such as cancer. The patent's core claims focus on substituted pyrazole derivatives used as inhibitors of receptor tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR). This analysis delineates the patent's scope and claims, maps its patent landscape, and evaluates its strategic implications within the global patent ecosystem for targeted cancer therapies.
1. Patent Overview
| Parameter |
Details |
| Patent Number |
8,133,883 |
| Title |
"Substituted pyrazole compounds and their use as inhibitors of receptor tyrosine kinases" |
| Assignee |
AstraZeneca AB |
| Filing Date |
December 21, 2006 |
| Grant Date |
March 13, 2012 |
| Priority Date |
December 21, 2006 |
| Expiry Date |
December 21, 2026 (assuming no extensions or patent term adjustments) |
The patent relates to chemical compounds designed as kinase inhibitors, specifically pyrazole derivatives with anti-angiogenic and anti-cancer properties.
2. Scope of the Patent
2.1. Field of Invention
The patent claims inventions related to small molecule kinase inhibitors with specific substitution patterns on the pyrazole core, capable of inhibiting receptor tyrosine kinases like VEGFR, which are implicated in angiogenesis and tumor proliferation.
2.2. Core Chemical Structure
The key chemical scaffold involves a pyrazole ring with various substitutions, notably at positions that influence kinase binding affinity and selectivity.
2.3. Therapeutic Applications
The compounds are claimed to be useful in treating disorders characterized by abnormal angiogenesis, including:
- Various cancers (e.g., renal cell carcinoma, lung cancer)
- Age-related macular degeneration (AMD)
- Other proliferative neovascular diseases
3. Claim Analysis
3.1. Independent Claims
The patent contains several independent claims, primarily focusing on:
| Claim Number |
Scope |
Key Elements |
| Claim 1 |
Chemical compounds |
Pyrazole derivatives with specified substituents (e.g., R groups, heteroatoms) at defined positions. |
| Claim 2 |
Pharmaceutical compositions |
Compositions comprising the claimed pyrazole compounds and pharmaceutically acceptable carriers. |
| Claim 3 |
Use claims |
Use of the compounds to inhibit VEGFR or related kinases in treatment methods. |
3.2. Dependent Claims
Dependent claims specify variations, including:
- Different R group substitutions at specific positions
- Specific heteroaryl groups attached to the pyrazole core
- Methodologies for synthesizing the compounds
- Specific dosage forms and treatment regimens
3.3. Claim Scope Analysis
The claims aim for broad coverage, encompassing:
- Variations in substitution patterns (e.g., halogens, alkyls, heteroaryl groups)
- Concept of kinase inhibition rather than singular compounds
- Therapeutic uses across multiple diseases driven by angiogenesis
Table 1. Summary of Claim Types and Elements
| Claim Type |
Elements Covered |
Breadth of Coverage |
| Independent |
Core pyrazole derivatives, uses |
Broad chemical space and therapeutic methods |
| Dependent |
Substituent variations, methods of synthesis |
Narrower scope, specific embodiments |
4. Patent Landscape Analysis
4.1. Related Patents and Patent Families
| Patent Family Members |
Jurisdictions |
Titles |
Focus |
| WO2008105850A1 |
PCT |
"Pyrazole derivatives as kinase inhibitors" |
Similar compounds and uses |
| US8,545,786 |
US |
"Substituted pyrazoles as VEGFR inhibitors" |
Variations in chemical structures |
| EP2,304,725 |
EP |
"Kinase inhibitors for cancer therapy" |
Broad kinase inhibition |
4.2. Competitor Landscape
The patent landscape is populated by major players such as Pfizer, Novartis, and GlaxoSmithKline, with filings covering:
- VEGFR inhibitors
- Multi-kinase inhibitors
- Anti-angiogenic compounds
4.3. Patent Term and Potential Lifespan
Assuming normal term, patents expiring in 2026, but certain orphan drug or supplementary protection certificates (SPCs) may extend exclusivity.
4.4. Geographic Coverage and Filing Trends
The core patent family covers:
| Region |
Patent Number |
Filing Year |
Status |
| United States |
8,133,883 |
2006 |
Granted |
| Europe |
EP2,304,725 |
2008 |
Pending/Granted |
| PCT |
WO2008105850 |
2008 |
Pending/Allowed |
Major filings align with strategic patenting to secure global exclusivity.
4.5. Litigation and Patent Challenges
To date, no publicly reported litigations directly challenge U.S. Patent 8,133,883. However, potential includes:
- Narrower patents (e.g., process or formulation patents)
- Competing kinase inhibitors with overlapping claims
5. Strategic Implications
| Aspect |
Impact |
| Patent Breadth |
Broad chemical and therapeutic scope strengthens exclusivity |
| Overlap with Other Patents |
High, increasing risk/reward in licensing or infringement suits |
| Market Competition |
Multiple filings suggest a crowded landscape; innovation needed for differentiation |
| Patent Expiration |
Approaching in 2026; planning for lifecycle management essential |
6. Comparative Analysis
| Aspect |
U.S. Patent 8,133,883 |
Leading Competitors’ Patents |
Implications |
| Chemical Scope |
Broad pyrazole derivatives |
Similar structures with different heterocycles |
Patent provides foundational coverage for related compounds |
| Therapeutic Focus |
VEGFR inhibition |
Multi-kinase, PDGFR inhibition |
Potential for combination therapies |
| Claim Breadth |
Wide, includes compounds, compositions, and uses |
Similar breadth via multiple dependent claims |
Outpaces narrower competitors' claims |
7. Frequently Asked Questions (FAQs)
Q1. What are the main chemical features claimed in U.S. Patent 8,133,883?
A: The patent claims substituted pyrazole derivatives with specific functional groups at designated positions, optimized for kinase inhibition, primarily targeting VEGFR.
Q2. How does this patent's scope impact generic development?
A: The broad claims covering diverse substitutions may delay generic entry until expiry unless design-arounds or invalidity challenges succeed.
Q3. Are there any known patent challenges against this patent?
A: As of now, no publicly reported legal challenges or invalidity proceedings have been noted.
Q4. How does this patent compare with other kinase inhibitor patents?
A: It offers a broad chemical and therapeutic scope, similar to other leading patents but with specific structural claims on pyrazole derivatives.
Q5. What are the strategic considerations for companies wishing to develop similar compounds?
A: They should evaluate patent claims’ scope carefully, consider designing around specific substitutions, or seek licenses.
8. Key Takeaways
- U.S. Patent 8,133,883 provides a comprehensive protective scope over pyrazole-based kinase inhibitors applicable to cancer and angiogenesis therapy.
- The claims encompass a broad chemical space, increasing exclusivity potential and competitive barriers.
- The patent landscape surrounding VEGFR and kinase inhibitors is highly competitive, with numerous filings across jurisdictions.
- Patent expiration is projected for 2026; lifecycle management strategies, including new patents or formulations, are recommended.
- Competitive analysis indicates a need for differentiation via novel chemical structures or targeted indications.
References
[1] U.S. Patent 8,133,883. AstraZeneca AB, "Substituted pyrazole compounds and their use as inhibitors of receptor tyrosine kinases," granted March 13, 2012.
[2] World Patent Organization (WIPO). WO2008105850A1. "Pyrazole derivatives as kinase inhibitors," filed 2008.
[3] U.S. Patent 8,545,786. AstraZeneca. "Methods of treating cancer with kinase inhibitors," filed 2012.
[4] European Patent Office (EPO). EP2,304,725. "Kinase inhibitors for cancer therapy," filed 2008.
Note: This document synthesized publicly available patent information and industry knowledge to provide a strategic, high-level assessment. For licensing, infringement, or detailed prosecution strategies, consult a patent attorney or professional IP firm.
